🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Big thanks to Federico Cappuzzo for organizing #RomeLung24 meeting in this beautiful eternal city, with insightful discussions on the latest lung cancer trial results by KOL panels. A pleasure to connect with many international colleagues! 👏👍🙏🔬

Why do some patients benefit less than others from precision cancer medicine? We are excited to share our paper "Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling” out in Nature Communications. nature.com/articles/s4146… 🧵

Reflecting on missd chanc to condct a 1L EGFRmut ILT with AZD9291 in UK in 2014. After prelim discs, AZ indpndny ran their own intl FLAURA trl with the drug now known as Osimertinib/Tagrisso. Proud to be assoc w/this UK-dev’d drug, which has imprvd the lives of mny EGFR+pts wrldw

Thank you AZ & Stephen V Liu, MD for highlight. our ctDNA analys. on FLAURA & AURA3 EGFR+pts receiving osimertinib JTO & JTO CRR. EGFR ctDNA PD dectection often prec./co-occ. RECIST PD, enabling earlier oppor. for discussion & planning before radiological PD. shorturl.at/aCHzK

🎉 Good news! EMA’s CHMP adopted a positive opinion for atezolizumab marketing authorization based on the IPSOS trial, recommending its approval for 1L treatment of advanced NSCLC pts who are ineligible for platinum-based therapy #IPSOS ema.europa.eu/en/medicines/h…

Tecentriq - opinion on variation to marketing authorisation | European Medicines Agency ema.europa.eu/en/medicines/h… Another impt milestone for our unmet need adv NSCLC pts unfit for platinum doublt chemotherapy following the 2024 NCCN Guidelines. 😃 #IPSOS #practicechangingtrial

🔥#WCLC24 🎯Challenges and Controversies in Immunotherapy 🌟Faculties🌟 ✅Clarissa Baldotto ✅Misako Nagasaka ✅Anil Tibdewal ✅@ArielleElkrief ✅David Gandara ✅ProfSiowMingLee #LCSM IASLC OncoAlert cattendee.abstractsonline.com/meeting/20598

Lear More about Challenges & Controversies in Immunotherapy from Clarissa Baldotto, Misako Nagasaka, Anil Tibdewal, @ArielleElkrief, David Gandara & ProfSiowMingLee, who are currently presenting at #WCLC24. #LCSM #IASLC50 #LungCancer

Honoured 🙏 to speak on mRNA lung cancer vaccine at our UCLH Annual Members Meeting. Reflecting on 30 yrs of clinical trials conducted and led here, transforming NSCLC treatment from hopelessness to hope with chemo, TKIs, IOs and possibly mRNA vaccines!

Honoured to have been Derek Crowther’s last ‘Senior Registrar’. Forever grateful for his appointment as a CRC Clinical Reseach Fellow in his Dept in 1989, which shaped my career. His pioneering legacy in medical oncology had left an indelible mark in UK. bit.ly/3Ulaf41

🙏Honoured and delighted to be invited as the 1st Plenary Speaker at the 12th EOC. My sincere thanks to the organising committee, Dr Balaraj and Dr Ansari, for the invite. Congratulations to both for organising this outstanding 12th EOC oncology meeting at Abu Dhabi👏💊 #research

Published! Don’t forget steroids for entrectinib-induced myocarditis, or even consider a trial of steroids for any TKI-induced myocarditis as well.🩺💊#Entrectinib #CardioOnc #Oncology jtocrr.org/article/S2666-…

🙏Honoured to be featured on front cover of @UCLHNews (2024) again after 23 years on @UCLNews (2001).🔬From early trials with thalidomide to mRNA’s potential, decades of research have transformed lung cancer treatment, inc. the IPSOS trial #UCLH #UCL #LungCancerResearch

📣🔬Our Study 15 results are now out! This is the 1️⃣st & only randomised trial with Hydroxychloroquine (HCQ) for SCLC. Combining HCQ with 1L platinum chemo didn’t improve PFS/OS, was assoc. with more G3/4 AEs, & fewer completed 4 cycles. Link: t.ly/KkL2M

💊🔬Grateful to see our research on Hydroxychloroquine for lung cancer featured by UCLH. Thank you to the hard work and collaboration of teams and investigators across UK to deepen our understanding of HCQ’s role in lung cancer. #CancerResearch #DrugDev #HydroxyChloroquine

Deeply grateful to Federico Cappuzzo and team for the honour of attending #RomeLung25 in the magnificent city of Rome—made even more historic by the election of a new Pope. Inspiring to connect with global colleagues and discuss the latest advances in lung cancer treatment.

💊 First-line atezolizumab shows benefit in NSCLC patients unfit for platinum-doublet chemotherapy. A plain language summary of the IPSOS trial is now available. 👉 Read more here: bit.ly/4kv1LSo #NSCLC #PoorPS #Immunotherapy

🙏 Honored to speak at the #BIGNCTN in Chicago with DavidBraun & John Haanen. Grateful to share lung cancer vaccine insights & join the discussion on the potential of #CancerVaccines & #CellularTherapies with breast cancer leaders inc Nancy Lin, MD Seamus O’Reilly MD PhD & GiuseppeCurigliano

🙏 Honored to be invited to the 10th @EconomistImpact World Cancer Series Europe in Brussels to discuss how mRNA cancer vaccines could help shape the next era of cancer treatment—interviewed by Elizabeth Sukkar, among health policymakers, pharma leaders & cancer experts. #CancerVaccines

The Immune System in Cancer: Its Roles and How We Can Harness It | Technology Networks technologynetworks.com/tn/articles/th…